

In the claims:

1. **(Currently amended)** A controlled release pharmaceutical delivery composition which provides sustained ~~or pulsatile~~ delivery of a selected pharmaceutically active substance for a predetermined period of time, said composition comprising;

- about 1-50% by weight polymers of acrylic acid crosslinked with polyalkenyl alcohols or divinyl alcohol;

- about 1 to ~~[[15]]~~ 58% by weight of a mixture of hydroxyethyl cellulose and hydroxypropyl methylcellulose;

- about 0<10% by weight talc; ~~[[and]]~~

- about 0<10% by weight magnesium stearate; and

-about 1-80% by weight of a pharmaceutically active agent;

wherein said acrylic acid crosslinked polymers, hydroxyethyl cellulose and hydroxypropyl methylcellulose, talc ~~[[and]]~~ magnesium stearate and pharmaceutically active agent are provided as a matrix.

2-3. **(Canceled).**

4. **(Previously presented)** The composition of claim 1, wherein said polymers of acrylic acid crosslinked with polyalkenyl alcohols or divinyl alcohol are carboxyvinyl polymer resins.

5-6. **(Canceled).**

7. **(Currently amended)** The composition of claim 1, wherein said composition is film coated with additionally comprises about 0.5 to 50% by weight of a coating material comprising anionic polymers based on methacrylic acid and methacrylic acid esters or neutral methacrylic acid esters with trimethylammonioethyl methacrylate chloride or cellulose esters.

8. **(Previously presented)** The composition of claim 1, wherein said composition additionally comprises 0<95% by weight granulating and tableting aids.

9. **(Currently amended)** A controlled release pharmaceutical delivery composition which provides sustained ~~or pulsatile~~ delivery of a selected pharmaceutically active substance for a predetermined period of time, said composition comprising;

- about 1 to ~~[[15]]~~ 58% by weight of a mixture of hydroxyethylcellulose and hydroxypropylmethyl cellulose;

- about 1 to 60% by weight of ethylcellulose;

- about 1 to 80% by weight of at least one carboxyvinyl polymer resin;

- about 0<10% by weight of talc;

- about 0<10% by weight of magnesium stearate; ~~[[and]]~~

- about 0<95% by weight granulating and tableting aids; and

- about 1-80% of a pharmaceutically active agent,

wherein said hydroxyethylcellulose, hydroxypropylmethyl cellulose, ethylcellulose, carboxyvinyl polymer resin, talc, magnesium stearate, ~~[[and]]~~ granulating and tableting aid, and pharmaceutically active agent are provided as a matrix.

10. **(Canceled).**

11. **(Currently amended)** The composition of claim 9 ~~[[10]]~~, wherein said pharmaceutically active agent is selected from the group consisting of naproxen, COX2 inhibitors, budesonide, venlafaxine, metoprolol, carbidopa, levodopa, carbamazepine, ibuprofen, morphine, pseudoephedrine, paracetamol, cisapride, pilocarpine, methylphenidine, nicardipine, felodipine, captopril, terfenadine, fenofibrate, aciclovir, zidovudine, moclobemide, potassium chloride, lamotrigine, cladribine, loratadine, pancrelipase, lithium carbonate, orphenadrine, procainamide, ferrous sulfate, risperidone, clonazepam, lovastatin, simvastatin, pravachol, ketorolac, hydromorphone, ticlopidine, seligiline, alprazolam, divalproex and phenytoin.

12. **(Previously presented)** The composition as claimed in claim 1 wherein, said composition additionally comprises one or more pharmaceutical excipients selected from the group consisting of

lactose, silicone dioxide, sodium lauryl sulphate, calcium phosphate, calcium sulphate, silicified microcrystalline cellulose, gelucire® and compritol®.

13-22. **(Canceled)**

23. **(Currently amended)** A pharmaceutical composition comprising;

- about 1 to 80% by weight pharmaceutically active agent;
- about 1 to 50% by weight of polymers of acrylic acid crosslinked with polyalkenyl alcohols or divinyl alcohol; and
- about 1 to ~~[[15]]~~ 58% by weight of a mixture of hydroxyethyl cellulose and hydroxypropyl methylcellulose; wherein said polymers of acrylic acid, hydroxyethyl cellulose and hydroxypropyl methyl cellulose, and pharmaceutically active agent are provided as a matrix.

24-27. **(Canceled)**.

28. **(Currently amended)** The composition of claim 23, wherein said composition ~~additionally comprises about~~ is film coated with about 0.5 to 50% by weight of a pharmaceutically acceptable film coating comprising anionic polymers based on methacrylic acid and methacrylic acid esters or neutral methacrylic acid esters with trimethylammonioethyl methacrylate chloride or cellulose esters.

29. **(Previously presented)** The composition of claim 23, wherein said pharmaceutically active agent is selected from the group consisting of naproxen, COX2 inhibitors, budesonide, venlafaxine, metoprolol, carbidopa, levodopa, carbamazepine, ibuprofen, morphine, pseudoephedrine, paracetamol, cisapride, pilocarpine, methylphenidine, nicardipine, felodipine, captopril, terfenadine, fenofibrate, aciclovir, zidovudine, moclobemide, potassium chloride, lamotrigine, cladribine, loratadine, pancrelipase, lithium carbonate, orphenadrine, procainamide, ferrous sulfate, risperidone, clonazepam, lovastatin, simvastatin, pravachol, ketorolac, hydromorphone, ticlopidine, seligiline, alprazolam, divalproex and phenytoin.

30. **(Currently amended)** A pharmaceutical composition comprising:

- about 1 to 80% pharmaceutically active agent;

- about 1 to ~~[[15]]~~ 58% by weight of hydroxyethylcellulose and hydroxypropylmethyl cellulose;

- about 1 to 60% by weight of ethylcellulose;

- about 1 to 50% by weight of at least one carboxyvinyl polymer resin;

- about 0<10% by weight of talc;

- about 0<10% by weight of magnesium stearate; and

- about 0< 95% by weight granulating and tableting aids, wherein said pharmaceutically active agent, hydroxyethyl cellulose and hydroxypropyl methylcellulose, ethylcellulose, talc, magnesium stearate, and granulating and tableting aids, are provided as a matrix.

31. **(Original)** The composition of claim 30, wherein said tableting and granulating aids are selected from the group consisting of silicone dioxide, lactose, microcrystalline cellulose, calcium phosphate and mannitol.

32. **(Canceled).**

33. **(Currently amended)** A pharmaceutical composition comprising;

- about 1 to 80% by weight pharmaceutically active agent;

- about 1 to 50% by weight of polymers of acrylic acid crosslinked with polyalkenyl alcohols or divinyl alcohol;

- about 1 to 58% by weight of a mixture of hydroxyethyl cellulose and hydroxypropyl methylcellulose; wherein said polymers of acrylic acid, hydroxyethyl cellulose and hydroxypropyl methylcellulose and the pharmaceutically active agent are provided as a matrix; and

- about 0.5 to 50% by weight of a coating material coating said matrix, said coating material comprising anionic polymers based on methacrylic acid and methacrylic acid esters or neutral methacrylic acid esters with trimethylammonioethyl methacrylate chloride or cellulose esters.